Jose Olague
Chief Tech/Sci/R&D Officer at ALPHA TEKNOVA, INC.
Profile
Jose Olague is currently the Vice President-Engineering at Alpha Teknova, Inc. He previously worked as the Director-Manufacturing Engineering & Maintenance at Intarcia Therapeutics, Inc. and as the Director-Manufacturing & Engineering at Avinger, Inc. He obtained an undergraduate degree from Instituto Tecnológico de Ciudad Juárez.
Jose Olague active positions
| Companies | Position | Start |
|---|---|---|
| ALPHA TEKNOVA, INC. | Chief Tech/Sci/R&D Officer | 2020-04-30 |
Former positions of Jose Olague
| Companies | Position | End |
|---|---|---|
| AVINGER, INC. | Corporate Officer/Principal | - |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Training of Jose Olague
| Instituto Tecnológico de Ciudad Juárez | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ALPHA TEKNOVA, INC. | Health Technology |
| AVINGER, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Jose Olague
